Wave Life Sciences, Inc. (WVE) SEC Filings, Jun 23, 2025

Wave Life Sciences Ltd. (“Wave”, Nasdaq: WVE) has released its definitive proxy statement (DEF 14A) for the 2025 Annual General Meeting of Shareholders ("2025 AGM") to be held at 11:30 a.m. ET on 5 August 2025 at 733 Concord Avenue, Cambridge, MA.

The filing asks shareholders to vote on governance, audit, compensation and share-issuance matters:

• Resolutions 1(a)-1(i): Election of nine directors, including CEO Paul B. Bolno and other incumbent board members.
• Resolution 2: Re-appointment of KPMG LLP as independent registered public accounting firm and Singapore auditor for FY 2025, with Audit Committee discretion over remuneration.
• Resolution 3: Approval of the cash and equity-based compensation program for non-employee directors as detailed in the proxy.
• Resolution 4: Amendment of the 2021 Equity Incentive Plan to add 8,000,000 ordinary shares for future awards.
• Resolution 5: Authority under Singapore Companies Act §161 for the Board to allot and issue ordinary shares or convertible instruments until the 2026 AGM.
• Resolution 6 (advisory): “Say-on-pay” vote approving compensation of named executive officers.
• Resolution 7 (advisory): “Say-on-frequency” vote recommending whether say-on-pay should occur every one, two or three years.

No financial results, earnings guidance or major strategic transactions are included; the document is strictly focused on shareholder governance, compensation policy and potential share issuance, elements that may influence dilution levels and board oversight going forward.